CL2014003465A1 - Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. - Google Patents

Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.

Info

Publication number: CL2014003465A1
Authority: CL; Chile
Prior art keywords: hegfr; binds; antibody; pharmaceutical composition; growth factor
Prior art date: 2012-06-25

Application number

CL2014003465A

Other languages

English (en)

Inventor

Christopher Daly

Gavin Thurston

Nicholas J Papadopoulos

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-25

Filing date

2014-12-19

Publication date

2015-02-27

2014-12-19 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2015-02-27 Publication of CL2014003465A1 publication Critical patent/CL2014003465A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL2014003465A 2012-06-25 2014-12-19 Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. CL2014003465A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261663984P	2012-06-25	2012-06-25
US201361821000P	2013-05-08	2013-05-08

Publications (1)

Publication Number	Publication Date
CL2014003465A1 true CL2014003465A1 (es)	2015-02-27

Family

ID=48782632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014003465A CL2014003465A1 (es)	2012-06-25	2014-12-19	Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.

Country Status (24)

Country	Link
US (3)	US9132192B2 (es)
EP (1)	EP2864357B1 (es)
JP (1)	JP6486268B2 (es)
KR (1)	KR20150023387A (es)
CN (1)	CN104411722B (es)
AR (1)	AR091545A1 (es)
AU (2)	AU2013280610B2 (es)
BR (1)	BR112014029099A2 (es)
CA (1)	CA2876697C (es)
CL (1)	CL2014003465A1 (es)
CO (1)	CO7160093A2 (es)
EA (1)	EA030421B1 (es)
ES (1)	ES2816645T3 (es)
HK (1)	HK1206040A1 (es)
IL (1)	IL235392B (es)
MX (2)	MX374463B (es)
MY (2)	MY164604A (es)
NZ (1)	NZ701633A (es)
PH (1)	PH12014502437A1 (es)
SG (3)	SG11201407163XA (es)
TW (2)	TWI641619B (es)
UY (1)	UY34876A (es)
WO (1)	WO2014004427A2 (es)
ZA (1)	ZA201407927B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH12014500483A1 (en)	2011-09-30	2014-04-14	Regeneron Pharma	Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) *	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9840560B2 (en) *	2013-03-15	2017-12-12	Alper Biotech Llc	Monoclonal antibodies to EGFR, and uses therefor
JP6771385B2 (ja)	2014-02-28	2020-10-21	メルスナムローゼフェンノートシャップ	二重特異性抗体および医薬組成物
EP4707303A2 (en)	2014-05-16	2026-03-11	Ablynx NV	Improved immunoglobulin variable domains
IL318433A (en)	2014-05-16	2025-03-01	Ablynx Nv	Improved immunoglobulin variable complexes
TWI870789B (zh)	2015-08-04	2025-01-21	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
CN105017424B (zh) *	2015-08-31	2021-02-09	北京泱深生物信息技术有限公司	一种egfr抗体可变区及其应用
SMT202100230T1 (it)	2015-10-23	2021-07-12	Fundacio Inst De Recerca Biomedica Irb Barcelona	Molecole di legame che inibiscono la crescita tumorale
MA43416A (fr)	2015-12-11	2018-10-17	Regeneron Pharma	Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
EP3504328A1 (en)	2016-08-24	2019-07-03	Regeneron Pharmaceuticals, Inc.	Host cell protein modification
IL269656B2 (en)	2017-03-31	2024-06-01	Merus Nv	Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja)	2017-05-17	2023-06-23	メルスナムローゼフェンノートシャップ	乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
BR112020000127A2 (pt)	2017-07-06	2020-07-07	Regeneron Pharmaceuticals, Inc.	método para selecionar um hidrolisado de soja, e, glicoproteína
SG11202001050PA (en)	2017-08-09	2020-03-30	Merus Nv	Antibodies that bind egfr and cmet
CN109912716B (zh) *	2017-12-13	2022-08-23	凯惠科技发展(上海)有限公司	一种egfr抗体及其制备方法和应用
MX2020006639A (es)	2017-12-22	2020-09-14	Regeneron Pharma	Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
BR112020013336A2 (pt)	2018-01-31	2020-12-01	Regeneron Pharmaceuticals, Inc.	produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
TW202311746A (zh)	2018-02-02	2023-03-16	美商再生元醫藥公司	用於表徵蛋白質二聚合之系統及方法
WO2019168774A1 (en)	2018-02-28	2019-09-06	Regeneron Pharmaceuticals, Inc.	Systems and methods for identifying viral contaminants
KR20200131838A (ko) *	2018-03-14	2020-11-24	에프. 호프만-라 로슈 아게	항체의 친화성 성숙화를 위한 방법
US12259355B2 (en)	2018-03-19	2025-03-25	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
HUE065344T2 (hu)	2018-03-19	2024-05-28	Regeneron Pharma	Mikrochip kapilláris elektroforézis assay-k és reagensek
US12253490B2 (en)	2018-03-19	2025-03-18	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
TW202016125A (zh)	2018-05-10	2020-05-01	美商再生元醫藥公司	用於定量及調節蛋白質黏度之系統與方法
CN108680746A (zh) *	2018-06-05	2018-10-19	中国科学院合肥物质科学研究院	一种控制肺癌细胞活力的分子靶标及其应用
CN119264211A (zh)	2018-08-27	2025-01-07	瑞泽恩制药公司	拉曼光谱在下游纯化中的应用
JP7511542B2 (ja)	2018-08-30	2024-07-05	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	タンパク質複合体を特徴づけるための方法
EA202190749A1 (ru)	2018-09-10	2021-07-09	Мирати Терапьютикс, Инк.	Способы комбинированной терапии
WO2020150491A1 (en)	2019-01-16	2020-07-23	Regeneron Pharmaceuticals, Inc.	Methods for characterizing disulfide bonds
CA3134335A1 (en)	2019-03-22	2020-10-01	Regeneron Pharmaceuticals, Inc.	Egfr x cd28 multispecific antibodies
WO2020231992A1 (en)	2019-05-13	2020-11-19	Regeneron Pharmaceuticals, Inc.	Improved competitive ligand binding assays
EP4005593A4 (en) *	2019-07-24	2023-08-16	Sinocelltech Ltd.	MULTIVARIABLE DOSING METHOD FOR USE IN THE TREATMENT OF HIGH EGFR EXPRESSION CANCER
WO2021061790A1 (en)	2019-09-24	2021-04-01	Regeneron Pharmaceuticals, Inc.	Systems and methods for chromatography use and regeneration
CA3158119A1 (en)	2019-11-25	2021-06-03	Regeneron Pharmaceuticals, Inc.	Sustained release formulations using non-aqueous emulsions
CN115398236B (zh)	2020-01-21	2024-06-11	瑞泽恩制药公司	用于糖基化的蛋白质的电泳的去糖基化方法
BR112022017048A2 (pt)	2020-02-26	2022-11-16	Vir Biotechnology Inc	Anticorpos contra sars-cov-2 e métodos para usar os mesmos
WO2022047108A1 (en)	2020-08-31	2022-03-03	Regeneron Pharmaceuticals, Inc.	Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2022115588A1 (en)	2020-11-25	2022-06-02	Regeneron Pharmaceuticals, Inc.	Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko)	2020-12-17	2023-08-21	리제너론 파아마슈티컬스, 인크.	단백질-캡슐화 마이크로겔의 제작
MX2023008527A (es)	2021-01-20	2023-07-28	Regeneron Pharma	Metodos para mejorar el valor proteico en cultivo celular.
JP2024512299A (ja)	2021-03-03	2024-03-19	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	タンパク質の粘度を定量及び変更するためのシステム及び方法
AU2022243005A1 (en)	2021-03-26	2023-10-05	Regeneron Pharmaceuticals, Inc.	Methods and systems for developing mixing protocols
US20230027739A1 (en)	2021-05-10	2023-01-26	Entrada Therapeutics, Inc.	Antigen-binding and antigen degradation constructs
BR112023024984A2 (pt)	2021-06-01	2024-02-20	Regeneron Pharma	Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
US20230077710A1 (en)	2021-09-08	2023-03-16	Regeneron Pharmaceuticals, Inc.	HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en)	2021-09-20	2023-03-23	Philip Mellors	Methods of controlling antibody heterogeneity
WO2023059803A1 (en)	2021-10-07	2023-04-13	Regeneron Pharmaceuticals, Inc.	Ph meter calibration and correction
CA3230984A1 (en)	2021-10-07	2023-04-13	Ross BROWNE	Systems and methods of ph modeling and control
TW202330104A (zh)	2021-10-26	2023-08-01	美商再生元醫藥公司	用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
CN116333119B (zh) *	2021-12-16	2024-02-23	徕特康(苏州)生物制药有限公司	抗表皮生长因子受体抗体及其制备方法和用途
KR20240164561A (ko)	2022-03-18	2024-11-19	리제너론 파아마슈티컬스, 인크.	폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
JP2025523802A (ja)	2022-07-13	2025-07-25	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	分析物を検出するための弱酸性免疫アッセイ
AU2023356866A1 (en)	2022-10-03	2025-04-17	Regeneron Pharmaceuticals, Inc.	Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
CN120129704A (zh) *	2022-11-01	2025-06-10	俄勒冈州健康与服务部	特异于fas配体的单克隆抗体及其用途
TW202435942A (zh)	2022-12-16	2024-09-16	美商里珍納龍藥品有限公司	評估層析管柱完整性的方法及系統
EP4655595A1 (en)	2023-01-25	2025-12-03	Regeneron Pharmaceuticals, Inc.	Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en)	2023-01-25	2024-07-25	Regeneron Pharmaceuticals, Inc.	Methods of modeling liquid protein composition stability
WO2024163708A1 (en)	2023-02-01	2024-08-08	Regeneron Pharmaceuticals, Inc.	Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
EP4669963A2 (en)	2023-02-22	2025-12-31	Regeneron Pharmaceuticals, Inc.	SYSTEM FITNESS PARAMETERS AND COLUMN AGING
US20240366471A1 (en)	2023-05-01	2024-11-07	Regeneron Pharmaceuticals, Inc.	Multidose antibody drug products using phenol or benzyl alcohol
CN121666401A (zh)	2023-07-10	2026-03-13	瑞泽恩制药公司	双特异性PD-L1x4-1BB抗体及其使用方法
WO2025014913A1 (en)	2023-07-10	2025-01-16	Regeneron Pharmaceuticals, Inc.	Bispecific pd-l1xcd28 antibodies and methods of use thereof
WO2025054406A1 (en)	2023-09-08	2025-03-13	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en)	2023-09-18	2025-03-20	Regeneron Pharmaceuticals, Inc.	Methods and systems for developing chromatography protocols
US20250109905A1 (en)	2023-09-29	2025-04-03	Regeneron Pharmaceuticals, Inc.	Lyophilization using controlled nucleation
US20250129117A1 (en)	2023-10-18	2025-04-24	Regeneron Pharmaceuticals, Inc.	Rapid purification of monoclonal antibody from in-process upstream cell culture material
CN117430707B (zh) *	2023-10-25	2024-04-19	重庆天科雅生物科技有限公司	一种cik细胞的制备方法及其在治疗癌症中的用途
US20250145662A1 (en)	2023-11-02	2025-05-08	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity using stress
WO2025166281A1 (en)	2024-02-01	2025-08-07	Regeneron Pharmaceuticals, Inc.	Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en)	2024-02-16	2025-08-21	Regeneron Pharmaceuticals, Inc.	Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
TW202602489A (zh)	2024-03-15	2026-01-16	美商再生元醫藥公司	作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
WO2025259840A1 (en)	2024-06-13	2025-12-18	Regeneron Pharmaceuticals, Inc.	Methods and systems for scaled chromatography
WO2026025028A1 (en)	2024-07-26	2026-01-29	Regeneron Pharmaceuticals, Inc.	Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026050255A2 (en)	2024-08-27	2026-03-05	Regeneron Pharmaceuticals, Inc.	Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
WO2026060350A1 (en)	2024-09-13	2026-03-19	Regeneron Pharmaceuticals, Inc.	Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en)	2024-10-03	2026-04-09	Regeneron Pharmaceuticals, Inc.	Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en)	2024-10-08	2026-04-16	Regeneron Pharmaceuticals, Inc.	Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en)	1991-06-14	2004-03-24	Genentech Inc.	Method for making humanized antibodies
PT699237E (pt)	1994-03-17	2003-07-31	Merck Patent Gmbh	Fvs de cadeia anti-egfr e anticorpos anti-egfr
US7060808B1 (en)	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
US20020173629A1 (en)	1997-05-05	2002-11-21	Aya Jakobovits	Human monoclonal antibodies to epidermal growth factor receptor
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
WO2002081649A2 (en) *	2001-04-06	2002-10-17	The Trustees Of The University Of Pennsylvania	ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en)	2001-06-13	2016-08-02	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7662374B2 (en) *	2001-08-03	2010-02-16	The Trustees Of The University Of Pennsylvania	Monoclonal antibodies to activated erbB family members and methods of use thereof
WO2004008099A2 (en) *	2002-07-15	2004-01-22	Genentech, Inc.	METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2005079434A2 (en) *	2004-02-17	2005-09-01	The University Of North Carolina At Chapel Hill	Modulation of epidermal growth factor heterodimer activity
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
WO2007042289A2 (en) *	2005-10-11	2007-04-19	Ablynx N.V.	Nanobodies™ and polypeptides against egfr and igf-ir
DK1951759T3 (da) *	2005-11-12	2010-05-10	Lilly Co Eli	Anti-EGFR-antistoffer
US7498142B2 (en)	2006-01-31	2009-03-03	Yeda Research And Development Co., Ltd.	Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
JP5307708B2 (ja)	2006-06-02	2013-10-02	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	ヒトｉｌ−６受容体に対する高親和性抗体
RU2448979C2 (ru)	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
DK2644194T3 (en) *	2008-03-18	2017-07-03	Genentech Inc	Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
TWI496582B (zh) *	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
MY152068A (en) *	2009-03-20	2014-08-15	Genentech Inc	Bispecific anti-her antibodies
EP2417164A1 (en) *	2009-04-07	2012-02-15	Roche Glycart AG	Bispecific anti-erbb-2/anti-c-met antibodies
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011156617A2 (en) *	2010-06-09	2011-12-15	Aveo Pharmaceuticals, Inc.	Anti-egfr antibodies

2013
- 2013-06-20 TW TW102121841A patent/TWI641619B/zh not_active IP Right Cessation
- 2013-06-20 TW TW107129255A patent/TW201843172A/zh unknown
- 2013-06-25 UY UY34876A patent/UY34876A/es unknown
- 2013-06-25 AU AU2013280610A patent/AU2013280610B2/en active Active
- 2013-06-25 MY MYPI2014003097A patent/MY164604A/en unknown
- 2013-06-25 NZ NZ701633A patent/NZ701633A/en not_active IP Right Cessation
- 2013-06-25 MY MYPI2017704291A patent/MY181086A/en unknown
- 2013-06-25 SG SG11201407163XA patent/SG11201407163XA/en unknown
- 2013-06-25 MX MX2018006118A patent/MX374463B/es unknown
- 2013-06-25 SG SG10201610590UA patent/SG10201610590UA/en unknown
- 2013-06-25 CA CA2876697A patent/CA2876697C/en active Active
- 2013-06-25 EP EP13735519.4A patent/EP2864357B1/en active Active
- 2013-06-25 CN CN201380033859.6A patent/CN104411722B/zh not_active Expired - Fee Related
- 2013-06-25 US US13/925,923 patent/US9132192B2/en active Active
- 2013-06-25 MX MX2014014361A patent/MX356329B/es active IP Right Grant
- 2013-06-25 ES ES13735519T patent/ES2816645T3/es active Active
- 2013-06-25 HK HK15106655.6A patent/HK1206040A1/xx unknown
- 2013-06-25 AR ARP130102231 patent/AR091545A1/es unknown
- 2013-06-25 JP JP2015518639A patent/JP6486268B2/ja active Active
- 2013-06-25 EA EA201590085A patent/EA030421B1/ru not_active IP Right Cessation
- 2013-06-25 WO PCT/US2013/047476 patent/WO2014004427A2/en not_active Ceased
- 2013-06-25 SG SG10201804151QA patent/SG10201804151QA/en unknown
- 2013-06-25 BR BR112014029099A patent/BR112014029099A2/pt not_active Application Discontinuation
- 2013-06-25 KR KR20147035064A patent/KR20150023387A/ko not_active Ceased
2014
- 2014-10-29 IL IL235392A patent/IL235392B/en active IP Right Grant
- 2014-10-30 PH PH12014502437A patent/PH12014502437A1/en unknown
- 2014-10-30 ZA ZA2014/07927A patent/ZA201407927B/en unknown
- 2014-12-19 CL CL2014003465A patent/CL2014003465A1/es unknown
- 2014-12-24 CO CO14283133A patent/CO7160093A2/es unknown
2015
- 2015-08-06 US US14/820,324 patent/US9789184B2/en active Active
2017
- 2017-09-11 US US15/700,665 patent/US20180036405A1/en not_active Abandoned
2018
- 2018-07-05 AU AU2018204895A patent/AU2018204895A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP6486268B2 (ja)	2019-03-20
WO2014004427A2 (en)	2014-01-03
PH12014502437B1 (en)	2015-01-12
ES2816645T3 (es)	2021-04-05
SG10201804151QA (en)	2018-07-30
HK1206040A1 (en)	2015-12-31
SG11201407163XA (en)	2014-11-27
NZ701633A (en)	2017-08-25
WO2014004427A8 (en)	2014-12-18
CA2876697C (en)	2021-07-13
MY181086A (en)	2020-12-17
AR091545A1 (es)	2015-02-11
TW201843172A (zh)	2018-12-16
US20130344093A1 (en)	2013-12-26
MX374463B (es)	2025-03-06
US9789184B2 (en)	2017-10-17
EP2864357B1 (en)	2020-07-01
AU2013280610B2 (en)	2018-04-26
EA030421B1 (ru)	2018-08-31
EP2864357A2 (en)	2015-04-29
US20150337043A1 (en)	2015-11-26
MX2014014361A (es)	2015-02-05
BR112014029099A2 (pt)	2017-07-18
TWI641619B (zh)	2018-11-21
EA201590085A1 (ru)	2015-04-30
JP2015521629A (ja)	2015-07-30
US20180036405A1 (en)	2018-02-08
ZA201407927B (en)	2015-11-25
CN104411722A (zh)	2015-03-11
PH12014502437A1 (en)	2015-01-12
US9132192B2 (en)	2015-09-15
TW201402610A (zh)	2014-01-16
IL235392B (en)	2019-02-28
AU2018204895A1 (en)	2018-07-26
WO2014004427A3 (en)	2014-03-27
MX356329B (es)	2018-05-24
CA2876697A1 (en)	2014-01-03
AU2013280610A1 (en)	2014-11-20
KR20150023387A (ko)	2015-03-05
CO7160093A2 (es)	2015-01-15
SG10201610590UA (en)	2017-02-27
CN104411722B (zh)	2017-11-17
UY34876A (es)	2013-12-31
MY164604A (en)	2018-01-30

Publication	Publication Date	Title
CL2014003465A1 (es)	2015-02-27	Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015000094A1 (es)	2015-06-19	Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2014001829A1 (es)	2015-01-02	Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014001547A1 (es)	2014-10-24	Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2013002517A1 (es)	2014-07-25	Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2014003227A1 (es)	2015-02-06	Compuestos derivados de imidazol condensados, como moduladores de la actividad del receptor del factor de crecimiento epidermico (egfr); composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de cancer colorrectal, de mama, de pancreas, de ovario, entre otros.
MX2016008131A (es)	2016-09-16	Compuestos heterociclos biciclicos y sus usos en terapia.
CL2014002726A1 (es)	2015-02-13	Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
CL2014000758A1 (es)	2014-08-22	Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral.
CL2016000153A1 (es)	2016-07-29	Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002735A1 (es)	2017-02-10	Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2012002189A1 (es)	2012-11-23	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2014001994A1 (es)	2014-11-03	Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CL2014002757A1 (es)	2015-01-23	Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
CL2014001865A1 (es)	2015-06-26	Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015001702A1 (es)	2015-08-07	Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2015001250A1 (es)	2015-08-14	Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros.
IL235261B (en)	2021-02-28	Antibodies against claudin 18.2 useful in cancer diagnosis
UY35399A (es)	2014-10-31	Conjugados de fármacos con anticuerpos
CL2011002877A1 (es)	2012-05-25	Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .